CN103889988B - Nedd8-活化酶的抑制剂 - Google Patents

Nedd8-活化酶的抑制剂 Download PDF

Info

Publication number
CN103889988B
CN103889988B CN201280052013.2A CN201280052013A CN103889988B CN 103889988 B CN103889988 B CN 103889988B CN 201280052013 A CN201280052013 A CN 201280052013A CN 103889988 B CN103889988 B CN 103889988B
Authority
CN
China
Prior art keywords
chemical entity
peaks
angles
chloro
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280052013.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103889988A (zh
Inventor
阿什利·苏·麦卡伦
托德·B·塞尔斯
马修·史提灵
斯蒂芬·G·斯特劳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN103889988A publication Critical patent/CN103889988A/zh
Application granted granted Critical
Publication of CN103889988B publication Critical patent/CN103889988B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280052013.2A 2011-08-24 2012-08-23 Nedd8-活化酶的抑制剂 Expired - Fee Related CN103889988B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161526830P 2011-08-24 2011-08-24
US61/526,830 2011-08-24
PCT/US2012/052007 WO2013028832A2 (en) 2011-08-24 2012-08-23 Inhibitors of nedd8-activating enzyme

Publications (2)

Publication Number Publication Date
CN103889988A CN103889988A (zh) 2014-06-25
CN103889988B true CN103889988B (zh) 2018-05-04

Family

ID=47747080

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280052013.2A Expired - Fee Related CN103889988B (zh) 2011-08-24 2012-08-23 Nedd8-活化酶的抑制剂

Country Status (29)

Country Link
US (3) US8809356B2 (enExample)
EP (2) EP2748168A4 (enExample)
JP (1) JP6038150B2 (enExample)
KR (1) KR20140054288A (enExample)
CN (1) CN103889988B (enExample)
AR (1) AR087672A1 (enExample)
AU (1) AU2012298813B2 (enExample)
BR (1) BR112014004239A2 (enExample)
CA (1) CA2846231C (enExample)
CL (1) CL2014000441A1 (enExample)
CO (1) CO6900148A2 (enExample)
CR (1) CR20140128A (enExample)
DO (1) DOP2014000037A (enExample)
EA (1) EA031067B1 (enExample)
EC (1) ECSP14013263A (enExample)
GE (1) GEP201606522B (enExample)
HK (1) HK1199252A1 (enExample)
IL (1) IL231069B (enExample)
MA (1) MA35439B1 (enExample)
MX (1) MX2014002015A (enExample)
MY (1) MY166889A (enExample)
PE (1) PE20141146A1 (enExample)
PH (1) PH12014500419A1 (enExample)
SG (2) SG10201601023UA (enExample)
TN (1) TN2014000080A1 (enExample)
TW (1) TWI577667B (enExample)
UA (1) UA114894C2 (enExample)
UY (1) UY34292A (enExample)
WO (1) WO2013028832A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
US9290500B2 (en) 2012-02-17 2016-03-22 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2014022744A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
US9695154B2 (en) 2013-07-02 2017-07-04 Millennium Pharmaceuticals, Inc. Heteroaryl inhibitors of sumo activating enzyme
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
PT3164130T (pt) * 2014-07-01 2019-11-18 Millennium Pharm Inc Compostos de heteroaril úteis como inibidores de enzima ativadora de sumo
WO2017183927A1 (ko) * 2016-04-20 2017-10-26 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018213258A1 (en) * 2017-05-15 2018-11-22 Millennium Pharmaceuticals, Inc. Treatment of merlin-deficient tumors using nae inhibitors
HUE068695T2 (hu) 2018-05-08 2025-01-28 Nippon Shinyaku Co Ltd Azabenzimidazol vegyületek és gyógyszerek
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101379061A (zh) * 2006-02-02 2009-03-04 千禧药品公司 E1活化酶抑制剂
CN101516850A (zh) * 2006-08-08 2009-08-26 米伦纽姆医药公司 适用作e1活化酶抑制剂的杂芳基化合物
WO2010132110A1 (en) * 2009-05-14 2010-11-18 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
AU6500696A (en) 1995-07-28 1997-02-26 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
WO2004043955A1 (en) 2002-11-13 2004-05-27 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
CA2596424C (en) 2005-02-04 2016-03-29 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
BR112014010699B1 (pt) * 2011-11-03 2020-12-15 Millennium Pharmaceuticals, Inc Uso de um inibidor nae com um agente de hipometilação para tratar malignidade hematológica e kit

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101379061A (zh) * 2006-02-02 2009-03-04 千禧药品公司 E1活化酶抑制剂
CN101516850A (zh) * 2006-08-08 2009-08-26 米伦纽姆医药公司 适用作e1活化酶抑制剂的杂芳基化合物
WO2010132110A1 (en) * 2009-05-14 2010-11-18 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Also Published As

Publication number Publication date
JP2014524476A (ja) 2014-09-22
EA031067B1 (ru) 2018-11-30
MA35439B1 (fr) 2014-09-01
CN103889988A (zh) 2014-06-25
MX2014002015A (es) 2014-03-27
HK1199252A1 (en) 2015-06-26
NZ622220A (en) 2016-04-29
EP3323414A1 (en) 2018-05-23
CA2846231A1 (en) 2013-02-28
TWI577667B (zh) 2017-04-11
CL2014000441A1 (es) 2014-09-26
TN2014000080A1 (en) 2015-07-01
JP6038150B2 (ja) 2016-12-07
US9850214B2 (en) 2017-12-26
MY166889A (en) 2018-07-24
ECSP14013263A (es) 2014-04-30
DOP2014000037A (es) 2014-04-15
CO6900148A2 (es) 2014-03-20
KR20140054288A (ko) 2014-05-08
AU2012298813A1 (en) 2013-05-02
CA2846231C (en) 2017-06-20
UA114894C2 (uk) 2017-08-28
IL231069B (en) 2018-02-28
EP2748168A4 (en) 2015-04-22
SG11201400102WA (en) 2014-03-28
BR112014004239A2 (pt) 2017-03-21
TW201313689A (zh) 2013-04-01
IL231069A0 (en) 2014-03-31
CR20140128A (es) 2014-05-15
AU2012298813B2 (en) 2016-07-28
AR087672A1 (es) 2014-04-09
US8809356B2 (en) 2014-08-19
GEP201606522B (en) 2016-08-10
WO2013028832A3 (en) 2013-05-02
PE20141146A1 (es) 2014-09-21
WO2013028832A2 (en) 2013-02-28
UY34292A (es) 2013-04-05
SG10201601023UA (en) 2016-03-30
PH12014500419A1 (en) 2020-06-22
EA201400249A1 (ru) 2014-05-30
EP2748168A2 (en) 2014-07-02
US20150011572A1 (en) 2015-01-08
US20180290983A1 (en) 2018-10-11
US20130150388A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
CN103889988B (zh) Nedd8-活化酶的抑制剂
US10202389B2 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
TWI481604B (zh) Novel 5-fluorouracil derivatives
WO2025078984A1 (en) Substituted tricyclic compounds as kras degraders
CN114269720B (zh) 乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂
TWI904095B (zh) 乙醯輔酶a合成酶短鏈2(acss2)之小分子抑制劑
WO2025223561A1 (zh) 一种喹唑啉酮并五元杂环化合物及其药用组合物和用途
TW202334097A (zh) 用於治療癌症之苯并【h】喹唑啉-4-胺衍生物
NZ622220B2 (en) Inhibitors of nedd8-activating enzyme
HK1238244A1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180504

Termination date: 20200823